

From: CN=Marc Falkin/OU=Anda/OU=Anda/O=Andrx
Sent: Thursday, November 1, 2007 4:55 PM
To: #Anda Pharmacy Group; CN=Wayne Tischler/OU=Anda/O=Andrx@Andrx; CN=Don Moore/OU=Anda/OU=Anda/O=Andrx@Andrx; Sorenson, Lori <Lori.Sorenson@andrx.com>; CN=Alison Libshtein/OU=Anda/O=Andrx@Andrx; CN=Linda Frazier/OU=Anda/O=Andrx@Andrx; Fields, George <George.Fields@andrx.com>; CN=Bart Marsala/OU=Anda/OU=Anda/O=Andrx@Andrx; CN=Kim Bloom/OU=Anda/O=Andrx@Andrx; Tauber, Meagan <Meagan.Tauber@Andrx.com>; Floro, Dominic <Dominic.Floro@andrx.com>; Mort, Renee <Renee.Mort@andrx.com>; CN=Tracy Paonessa/OU=VIP/O=Andrx@Andrx; Sciortino, Paul <Paul.Sciortino@andrx.com>; CN=Jeremy Tierney/OU=VIP/O=Andrx@Andrx; CN=Randy Saal/OU=Anda/O=Andrx@Andrx; #VIP Sales; Gross, Becky <Becky.Gross@andrx.com>; CN=Carrie Bennett/OU=Anda/OU=Anda/O=Andrx@Andrx; Cochrane, Michael <Michael.Cochrane@andrx.com>; Cochrane, Patrick <Patrick.Cochrane@andrx.com>; Spellman, Jay <Jay.Spellman@andrx.com>; CN=Alberto Esteves/OU=Anda/O=Andrx@Andrx; Paonessa III, Al <Al.Paonessa3@Watson.com>; CN=Al Paonessa VIP/OU=VIP/O=Andrx@Andrx; CN=Leslie Harrington/OU=Anda/OU=Anda/O=Andrx@Andrx; Kaus, Tina <Tina.Kaus@Andrx.com>; Goldfarb, Rachelle <Rachelle.Goldfarb@andrx.com>; CN=Darlene Hoover/OU=VIP/O=Andrx@Andrx; CN=Monica Mejia/OU=Anda/O=Andrx@ANDRX; CN=Elizabeth Shefferman/OU=Anda/O=Andrx@Andrx; Leon-Laurent, Christine <Christine.Leon-Laurent@andrx.com>; CN=Kim Bloom/OU=Anda/O=Andrx@Andrx; CN=Jennifer Jaumotte/OU=Anda/O=Andrx@Andrx; CN=Ryan Patton/OU=Anda/O=Andrx@Andrx; Alfaras, Carlos <Carlos.Alfaras@Andrx.com>; CN=Norman Dodes/OU=Anda/OU=Anda/O=Andrx@Andrx; Gretchen.Baker@Andrx.com; CN=Michelle Kelly/OU=Anda/O=Andrx@Andrx; Hayer, Joshua <Josh.Hayer@Andrx.com>; CN=Constantine Moshos/OU=Anda/O=Andrx@Andrx; #Anda Pricing and Contracts; Trotman, Lorrie <Lorrie.Trotman@Andrx.com>; Ossa, Pam <pam.ossa@andrx.com>; CN=Cathy Novaro/OU=Anda/O=Andrx@Andrx; CN=Carolina Sanchez/OU=Anda/O=Andrx@Andrx; CN=Althea McLean/OU=Anda/O=Andrx@Andrx; Mulligan, Gavin <gavin.mulligan@andrx.com>; Tauber, Meagan <Meagan.Tauber@Andrx.com>; Witte, Brian <brian.witte@andrx.com>; CN=Miguel Palma/OU=Anda/O=Andrx@Andrx; Cazzell, Jerry <Jerry.Cazzell@andrx.com>; Daum, Jeffrey <Jeffrey.Daum@andrx.com>; CN=John Jefferson/OU=AndrxPharm/O=Andrx@Andrx; CN=Richard Cunningham/OU=Anda/O=Andrx@Andrx; CN=Bill Versosky/OU=Anda/O=Andrx@Andrx; CN=Michael Porter/OU=Anda/O=Andrx@Andrx; CN=December Therrien/OU=Anda/O=Andrx@Andrx; CN=Ed Smith/OU=Anda/O=Andrx@Andrx; Barrett, Jay <Jay.Barrett@Andrx.com>; Martin, Karen <Karen.Martin@Andrx.com>; Gross, Becky <Becky.Gross@andrx.com>; CN=Carrie Bennett/OU=Anda/OU=Anda/O=Andrx@Andrx
Subject: OXYCODONE FAMILY LIMITS REVIEW
Attach: Narcotic Product Family Listing 110107.xls

This will confirm that we have formally broken out the OXYCODONE family into 2 product families for purposes of setting pill count limits. Each family will have the limit capacity.

PLAINTIFFS TRIAL
EXHIBIT
P-01714_00001

Oxycodone
&
Oxycodone Combo

An updated list of all the items we stock in all 26 product families is attached for your reference.

OCTOBER STAT OF THE MONTH

Only 9.5% of all customers (1452 total) who ordered some type of Oxycodone product from us (before we broke out the families) reached their pill count limit.

Others were close but most had excess capacity to purchase if needed. We will still review customers on a case by case basis but it seems the current limits are set to give the sales team opportunity to sell these categories of products, especially the 4 Dava Oxycodone CR.

As the list changes, we will send updates.

Please do not reply to all, see your sales manager, Kim or myself with questions.

Marc Falkin
Vice President, Marketing
Anda, Inc.
p. 954-217-4177
f. 954-217-4361

Produced in Native Format